Review
Lifestyle intervention and anti-obesity therapies in patients with polycystic ovary syndrome
Xiangyan Ruan, Muqing Gu
Published 2017-12-25
Cite as Chin J Reprod Contracep, 2017, 37(12): 1024-1027. DOI: 10.3760/cma.j.issn.2096-2916.2017.12.014
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in women of reproductive age. Lifestyle interventions, including diet, exercise and behavioral modification, improving the metabolic abnormalities of overweight and obese patients with PCOS, are recommended as first-line treatment. Lifestyle interventions combined with anti-obesity products, may exert more effects improving endocrine abnormalities of overweight/obese PCOS patients. Anti-obesity products include orlistat, metformin, and inositol can be effective in decreasing weight or improving PCOS manifestations. However, only orlistat is approved for obesity treatment. Moreover, bariatric surgery is efficient in achieving significant weight loss for obese PCOS women. In the paper, we reviewed and summarized the recently related studies.
Key words:
Polycystic ovary syndrome (PCOS); Lifestyle intervention; Anti-obesity therapies; Orlistat
Contributor Information
Xiangyan Ruan
Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijng 100026, China
Muqing Gu
Department of Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijng 100026, China